glp 1 receptor agonists beyond their pancreatic effects the pancreas: contrasting cardiometabolic actions of GIP and GLP1 Exploring the Side Effects of

Like tirzepatide, it targets two receptors simultaneously

Coexisting conditions affecting the tumor risk of GLP-1RAs Metabolic diseases Large-scale clinical studies have confirmed that the use of GLP-1RAs in diabetic populations does not increase the cancer risk occurrence

Increasingly, the medical community and the general public understand obesity to be a chronic, relapsing illness, as opposed to an overall moral failure

Kushner, R

In addition to improving glycemic control, the administration of these drugs causes a drastic drop in appetite and caloric intake

144 GLP-1RAs and gastrointestinal cancers GLP-1 and its receptor agonists show some potential in the treatment of gastrointestinal cancers, although this remains an emerging area of research